B7‐H3 is a potent inhibitor of human T‐cell activation: No evidence for B7‐H3 and TREML2 interaction

Abstract

B7-H3 belongs to the B7 superfamily, a group of molecules that costimulate or downmodulate T-cell responses. Although it was shown that B7-H3 could inhibit T-cell responses, several studies -most of them performed in murine systems -found B7-H3 to act in a costimulatory manner. In this study, we have specifically addressed a potential functional dualism of human B7-H3 by assessing the effect of this molecule under varying experimental conditions as well as on different T-cell subsets. We show that B7-H3 does not costimulate human T cells. In the presence of strong activating signals, B7-H3 potently and consistently down-modulated human T-cell responses. This inhibitory effect was evident when analysing proliferation and cytokine production and affected naïve as well as pre-activated T cells. Furthermore, we demonstrate that B7-H3-T-cell interaction is characterised by an early suppression of IL-2 and that T-cell inhibition can be reverted by exogenous IL-2. Since the triggering receptor expressed on myeloid cells like transcript 2 (TREML2/TLT-2) has been recently described as costimulatory receptor of murine B7-H3 we have extensively analysed interaction of human B7-H3 with TREML2/TLT-2. In these experiments we found no evidence for such an interaction. Furthermore, our data do not point to a role for murine TREML2 as a receptor for murine B7-H3. Key words: Costimulatory molecules . Immune regulation . T cells Supporting Information available online IntroductionFor fine-tuning the immune response, several costimulatory and coinhibitory signals are needed, in addition to signal 1 provided via the peptide-MHC/TCR-complex interaction. CD80 (B7-1) and CD86 (B7-2) serve as primary costimulatory ligands. Recently, additional members of the B7 family -the so-called B7 homologshave been identified [1]. The functional role of several of these B7 homologs is still controversially discussed. One of these molecules is B7-H3, which was originally described as a potent costimulatory molecule and inducer of IFN-g in human T cells [2]. In contrast, Ling et al. found human B7-H3 to strongly down-regulate T-cell proliferation and cytokine production [3]. It was suggested that the presence of two B7-H3 receptors with different functions could explain these divergent results [3]. Recent data that showed opposing effects of B7-H3 on resting and cytokine-activated T cells as well as contradicting results on the function of murine B7-H3 would also be in support for such a constellation [4][5][6][7]. Such receptor molecules could either be differentially regulated on T cells or be expressed on different T-cell subsets. Depending on the experimental system used the effects of the costimulatory or the inhibitory receptor could prevail and explain the discrepancies in different studies.Here, we have specifically addressed a potential functional dualism of B7-H3 by studying B7-H3 effects under varying experimental conditions as well as on different subsets of human T cells. Our results point to a potent and consistent inhibitory role of h...

Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma

“…Hashiguchi et al (13) have previously proposed TLT-2 as a counter-receptor to B7-H3. Furthermore, the same authors considered that the TLT-2/B7-H3 pathway costimulates T cell activation; however, alternative studies identified no evidence of an interaction between B7-H3 and TLT-2 (35). The data presented in the current study demonstrated a similar expression pattern of TLT-2 and B7-H3 in OSCC and healthy oral mucosa specimens.…”

B7-H3 Participates in the Development of Experimental Pneumococcal Meningitis by Augmentation of the Inflammatory Response via a TLR2-Dependent Mechanism

“…Although the definitive counterreceptors for B7- H3 have not yet been identified, previous work revealed that B7-H3 binds to a putative receptor expressed on PHA-or anti-CD3 mAb-activated T cells that is distinct from CD28, CTLA-4, ICOS, and programmed death-1 (12,16). A recent study identified triggering receptor expressed on myeloid cell-like transcript 2 as a costimulatory receptor for murine B7-H3 (17), but further work on both human and murine B7-H3 did not support this finding (18). Nevertheless, it has been postulated that multiple counterreceptors for B7-H3 may exist on different types of immune cells (17,19).…”

B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity

“…The physiological and pathological role of B7-H3 remains contentious, with stimulatory (4,15,16) and inhibitory (17)(18)(19) immunoregulatory functions in cellular and antitumor immune response described in early studies. Currently, the non-immunological functions of B7-H3 in cancer progression and chemoresistance have received increasing attention.…”